Liang Sun

Liang Sun

Auto-generated profile, based on publicly available information

Liang Sun

Department of Food Science and Human Nutrition

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLiang Sun
Liang Sun
YJYong-Su Jin
Yong-Su Jin
SYSangdo Yook
Sangdo Yook
SLStephan Lane
Stephan Lane
ZSZiqiao Sun
Ziqiao Sun
YJYong-Su Jin
Yong-Su Jin
Plant cell wall hydrolysates contain not only sugars but also substantial amounts of acetate, a fermentation inhibitor that hinders bioconversion of lignocellulose. Despite the toxic and non-consumable nature of acetate during glucose metabolism, we demonstrate that acetate can be rapidly co-consumed with xylose by engineered Saccharomyces cerevisiae. The co-consumption leads to a metabolic re-configuration that boosts the synthesis of acetyl-CoA derived bioproducts, including triacetic acid lactone (TAL) and vitamin A, in engineered strains. Notably, by co-feeding xylose and acetate, an enginered strain produces 23.91 g/L TAL with a productivity of 0.29 g/L/h in bioreactor fermentation. This strain also completely converts a hemicellulose hydrolysate of switchgrass into 3.55 g/L TAL. These findings establish a versatile strategy that not only transforms an inhibitor into a valuable substrate but also expands the capacity of acetyl-CoA supply in S. cerevisiae for efficient bioconversion of cellulosic biomass.



4 June 2023 in Food Hydrocolloids
Verified
Journal Article
Closed access
MNMaheshati Nuerjiang
Maheshati Nuerjiang
XBXue Bai
Xue Bai
LSLiang Sun
Liang Sun
QWQian Wang
Qian Wang
XXXiufang Xia
Xiufang Xia
FLFangfei Li
Fangfei Li

30 November 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
YLYe‐Gi Lee
Ye‐Gi Lee
CKCHANWOO KIM
CHANWOO KIM
LSLiang Sun
Liang Sun
TLTae‐Hee Lee
Tae‐Hee Lee
YJYong-Su Jin
Yong-Su Jin

5 December 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DXDahai Xu
Dahai Xu
NXNing Xu
Ning Xu
LSLiang Sun
Liang Sun
ZYZhaoying Yang
Zhaoying Yang
MHMiao He
Miao He
YLYoujun Li
Youjun Li
Background: Breast cancer (BC) is the most common malignant tumor among women worldwide. Tissue transglutaminase 2 (TG2) has been reported as a major player across several types of cancer. However, the effects of TG2 in breast cancer are less known. Methods: The expression of TG2 in patients with BC was detected by immunochemistry staining and RT-qPCR. The correlation of TG2 expression and clinicopathological factors or overall survival (OS) was analyzed by Chi-square test, Kaplan-Meier, and Cox-regression analysis. The effects of TG2 on cell proliferation and glycolysis were investigated in vivo and in vitro by gain- and loss-of-function experiments. Result: Both mRNA and protein levels of TG2 were overexpressed in BC tissues and cultured cells. Clinical stage (p = 0.011), molecular subtype (p<0.001) and survival status (p<0.001) were significantly correlated with TG2 expression. Specifically, TG2 expression was positively associated with the clinical stage (r = 0.193, p = 0.005) and OS (r = 0.230, p = 0.001), while negatively associated with molecular subtype (r = − 0.161, p = 0.020). Overexpressed TG2 was a prognostic factor of poor OS by Cox-regression analysis. Gain- and loss-of-function experiments indicated that cell proliferation and glycolysis were regulated by TG2 via the MEK/ERK/LDH pathway. TG2-induced activation of the MEK/ERK/LDH pathway and glycolysis were attenuated by MEK inhibitor U0126. Conclusion: TG2 is overexpressed in BC, which can serve as an independent prognostic factor for OS. TG2 promotes tumor cell proliferation and increases glycolysis associated with the activation of the MEK/ERK/LHD pathway.